NUVL: Nuvalent Inc Price-to-Revenue Multiple

Symbol and logo of brand Nuvalent Inc (NUVL)

The P/S ratio of Nuvalent, Inc. (NUVL) reflects a shift in market expectations, where the value of corresponds to the current metric. Previously, the financial stability of Nuvalent, Inc. (NUVL) relied on fund support and liquidity reserves independent of market cycles. Today, growth is driven by the development of drugs that overcome tumor resistance, while physical drug production is delegated to contract partners, linking operational resilience to the reliability of global supply chains.

NUVL Nuvalent Therapeutics Market Cap to Revenue (07/04/2022 - 11/15/2026)

Analytical breakdowns for Nuvalent (NUVL)

- share price and consensus valuation forecast:
Price Performance Chart Nuvalent|NUVL - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Nuvalent Therapeutics|NUVL - Enterprise Value
- book capitalization data:
Net Asset Value per Share Nuvalent|NUVL - Company Net Assets|Market Cap to Book Value Multiple nuvalent.com|NUVL - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Nuvalent, Inc.|NUVL - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Nuvalent|NUVL - Company Total Debt|Debt to Net Assets Ratio Nuvalent, Inc.|NUVL - Company Long-Term Liabilities|Amount of Current Liabilities Nuvalent|Intermediate Coverage Ratio nuvalent.com
- earnings and multiples data:
NUVL - Net Profit|Expected Net Profit Nuvalent, Inc.|NUVL - Price to Earnings Ratio|Future Price to Earnings Multiple Nuvalent Corp|NUVL - PEG Multiple|EV/EBITDA Multiple Nuvalent|NUVL - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Nuvalent|NUVL - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months nuvalent.com|NUVL - Earnings per share growth in current year|Projected earnings per share growth rate for next year Nuvalent, Inc.
- sales revenue and business income indicators:
NUVL - Company Sales|Projected Sales Volume Nuvalent Corp|NUVL - Market Cap to Revenue|Price-to-Projected Revenue Ratio Nuvalent Therapeutics|NUVL - Sales Growth YoY (TTM)
Summary company analytics:Nuvalent Corp, NUVL
Mass-produced product of nuvalent.com

The P/S multiple compares market capitalization to annual sales volume, reflecting the premium the market is willing to pay for each unit of revenue. For Nuvalent, Inc. (NUVL), which develops breakthrough drugs in targeted oncology, this serves as a gauge of capitalization growth potential, allowing the current price-to-sales ratio to determine whether the innovative asset is fundamentally overheated or undervalued.

Who Nuvalent, Inc. competes with

GMAB (Genmab) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis Inc)|Price-to-Revenue Multiple Kymera Therapeutics Inc|IDEAYA Biosciences Inc - P/S Multiple|Price to Sales Enliven Therapeutics, Inc.|ORIC (ORIC Pharmaceuticals) - Market Cap to Revenue|RLAY: Market Cap to Sales Volume|NRIX (nurixtx.com) - P/S Multiple|Price to Sales Tyra Bio TYRA|P/S Multiple VSTM|Monte Rosa Therapeutics, Inc. - Market Cap to Revenue Ratio|Cullinan Therapeutics, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMRX|CCCC: Market Cap to Revenue|Black Diamond Therapeutics Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales propanc.com PPCB|Price-to-Revenue Ratio Cyclacel Pharmaceuticals (BGMS)|AADI (Aadi Bioscience, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics Inc)|P/S Multiple Blueprint Medicines BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX